Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X SyndromeSAN...
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024 / The Patient-Centered Outcomes Research Institute (PCORI) awarded Patients for Patient Safety...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and...
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals...
GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics...
PARKERSBURG, WV / ACCESSWIRE / May 3, 2024 / Discovery World on Market is teaming up with Fight4Vets and Jan...
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low...
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline...
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage...
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines,...
SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on...
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months...
Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business developmentMARLBOROUGH, Mass....
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)...
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2...
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing...